

For sixteen years, Purim Ventures has done the work most investors only underwrite — inside companies, beside founders, through the hard middle of building.
Purim Capital is the investment firm built on that foundation. Where the studio builds companies, the firm provides the capital — a family of focused vehicles, each concentrated where the platform’s operating depth gives investors an advantage that capital alone cannot buy.
Purim Capital Fund I is dedicated to the arena where the studio’s bench runs deepest, healthcare and life sciences.


Most startups don’t fail from lack of innovation. They fail in execution. Purim engages as an institutional co-founder — surrounding founders with senior operators, proven playbooks, and the relationships that move a company from promise to proof. Our continued engagement after the close is a condition of every investment we make.
Fund I invests in early-stage healthcare and life sciences companies — Seed through Series A — that are genuinely disruptive to the current standard of care: lower cost, better outcomes, defensible advantage. We concentrate where the platform’s operating bench, clinical network, and distribution relationships materially change the odds. Concentrated portfolio. Negotiated entry. Reserves held for demonstrated winners.

Validated through our global network of researchers, physicians, and subject-matter experts. In our zones of expertise; disruptive to the segment; lower cost, better results.
Passed the full 90-day Mastermind. Founding team has relevant experience, is coachable, and works with us — so our network can drive value.
Sober-minded and independently validated. Will our family office network follow on behind us?
Leverages what Purim has already built, deployed, or invested in — compounding advantages across the portfolio.
Deployed capital must reach a positive valuation inflection within 6–18 months: revenue, major milestones,, or an international or strategic deal.
A credible, influenceable path to a venture-scale outcome within the Fund’s horizon — with exit routes (strategic acquisition, PE recap, public markets) evaluated from day one.
Copyright © 2026 Purim Capital - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.